LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TRVN) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On May 2, 2016, Trevena announced that it had “reached general agreement” with the U.S. Food and Drug Administration concerning key elements of its Phase 3 program for oliceridine (TRV130). Then the FDA released a briefing document in advance of its October 11, 2018 vote on the efficacy and safety of the treatment; in this briefing document the reviewers noted that oliceridine has abuse and overdose potential. On this news, shares of Trevena fell $1.91 or 64%, to close at $1.07 on October 9, 2018, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased Trevena securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
